by Daniel Hines
Publisher, RxforAmericanHealth
Even before reading this article, I suggested that perhaps Mylan was
implementing a ‘play’ upon the American pubic…first with the price increases, then with the rapid price decreases,
and now the move with a ‘new generic’ ...seems to me to be actions designed to
allow Mylan to take the steps necessary to enter the market with a ‘generic’
and Teva must wait until 2017 with approval and a new review, by which time
Mylan will control the generic segment of this market. While the introduction of
the generic is not included in this story, the article deals with the PhRMA PR
campaign and mind-set of an industry that has ‘played’ the American Public and
Congress for decades...
http://www.rawstory.com/2016/08/the-epipen-scandal-runs-deeper-than-most-of-us-realize/
Making the case for personal importation of safe, affordable prescription medicines from licensed, registered pharmacies in Tier One Countries. Rx for American Health is published by Daniel Hines, an international award-winning communicator with five decades of experience, and the publisher of www.TodaysSeniorsNetwork.com and www.BoomersNewsOnline.com. He also works with progressive senior advocacy groups across the nation to promote the health and well-being of America’s aging population.
Kaiser Poll Show Support for Personal Imporatation
No comments:
Post a Comment